13F
← All fund report cards

Invst, LLC

13F equity value
$884M
Positions
331
Top 10 concentration
29.5%
Quarters / total new picks
32 / 402
13F equity value over time
$0M$460M$920M2017201820192020202120222023202420252026

"13F equity value" = market value of this filer's US-listed long equity positions only. It excludes cash, bonds, non-US and short positions, so it understates a fund's true assets under management — often by a lot.

Not significant Verdict

13F holdings are disclosed ~45 days after quarter-end, and they never reveal when within the quarter a fund actually bought. So any 13F-based summary is structurally late and blurred — this applies to every fund, including this one.

We backtested copying it anyway. Buying this fund's new positions the day each filing went public, over 32 quarters, returned +3.5% per quarter — versus +2.7% per quarter from simply owning every 13F stock. It beat that baseline in only 62.5% of quarters (excess t = -0.51, not statistically significant). Its filings tell you what it bought — not what you should buy.

Avg 2Q excess
-1.3%
t-stat
-0.51
Quarterly win rate
63%
Annualized excess
+1.2%
$1 → follow vs universe
$2.27 vs $2.09
Cumulative return: $1 invested in new picks vs universe
1.00 20180331: universe 1.04120180630: universe 0.95920180930: universe 1.00320181231: universe 0.99220190331: universe 0.97520190630: universe 1.04820190930: universe 1.12720191231: universe 0.90920200331: universe 1.09620200630: universe 1.21120200930: universe 1.48520201231: universe 1.55320210331: universe 1.56620210630: universe 1.69220210930: universe 1.51920211231: universe 1.29220220331: universe 1.38720220630: universe 1.28520220930: universe 1.38120221231: universe 1.28220230331: universe 1.35120230630: universe 1.30320230930: universe 1.47920231231: universe 1.54520240331: universe 1.58020240630: universe 1.72320240930: universe 1.70820241231: universe 1.59420250331: universe 1.73820250630: universe 1.79320250930: universe 2.01620251231: universe 2.085 20180331: follow 1.07120180630: follow 0.96220180930: follow 0.99120181231: follow 1.00820190331: follow 1.01520190630: follow 1.22720190930: follow 1.55420191231: follow 1.57820200331: follow 1.75920200630: follow 1.99620200930: follow 2.50420201231: follow 2.29120210331: follow 2.36120210630: follow 2.37220210930: follow 1.56620211231: follow 1.54120220331: follow 1.57420220630: follow 1.53220220930: follow 1.07120221231: follow 1.10220230331: follow 1.17320230630: follow 1.07120230930: follow 1.20420231231: follow 1.28120240331: follow 1.33620240630: follow 1.45820240930: follow 1.42920241231: follow 1.41720250331: follow 1.52420250630: follow 1.58820250930: follow 1.85620251231: follow 2.269 0.84 1.77 2.70 20182019202020212022202320242025 Follow Universe

Quarterly compounding, invested quarters only · entry 47 days after quarter-end (when 13F data becomes public)

Listed as facts. See the verdict above before treating this as signal.

Top 20 holdings of 331 · 2026 Q1

Ticker Value Weight QoQ
VTI $52M
5.9%
TRIM
SPMO $35M
3.9%
HOLD
SCHG $29M
3.3%
TRIM
VEA $27M
3.1%
TRIM
LQD $21M
2.4%
ADD
IVV $21M
2.4%
ADD
IUSB $20M
2.3%
TRIM
SCHF $18M
2.1%
HOLD
HYG $18M
2.1%
ADD
EMB $18M
2.0%
TRIM
VTV $18M
2.0%
ADD
JCPB $17M
2.0%
ADD
DFIV $16M
1.8%
TRIM
IVE $16M
1.8%
TRIM
FRDM $15M
1.7%
TRIM
IEMG $15M
1.7%
TRIM
IVW $14M
1.6%
HOLD
DYNF $13M
1.5%
TRIM
DFAS $12M
1.4%
TRIM
JPST $11M
1.2%
ADD

QoQ vs previous quarter's share count · NEW = new position · ADD/TRIM = ±2% shares · HOLD = unchanged.

Listed as facts. See the verdict above before treating this as signal.

New positions in 2026 Q1

Method & Limitations

Method: a "new position" = held this quarter, absent last quarter (options excluded; stocks with <50 prior holders excluded to filter spin-off artifacts). Entry 47 days after quarter-end — the first day the public could act on the filing. Benchmark = equal-weighted universe of all 13F-held stocks. Limitations: quarterly snapshots can't see intra-quarter trades; survivorship bias — funds that shut down are absent, which flatters the sample. Statistics, not advice.